RNA helicase DDX3: A novel therapeutic target in Ewing sarcoma

Oncogene

Volumn 35, Issue 20, 2016, Pages 2574-2583

  Wilky, B A ^a,d   Kim, C ^a   McCarty, G ^a   Montgomery, E A ^b   Kammers, K ^c   Devine, L R ^b   Cole, R N ^b   Raman, V ^a,b   Loeb, D M ^a  

^a JOHNS HOPKINS UNIVERSITY   (United States)

^b JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

^d UNIVERSITY OF MIAMI   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALDEHYDE DEHYDROGENASE; ANTINEOPLASTIC AGENT; CASPASE 3; DOXORUBICIN; ETOPOSIDE; MESSENGER RNA; PROTEASOME; PROTEIN DDX3; PROTEIN DDX3 INHIBITOR; PROTEOME; RK 33; RNA HELICASE; SHORT HAIRPIN RNA; UNCLASSIFIED DRUG; AZEPINE DERIVATIVE; DDX3X PROTEIN, HUMAN; DEAD BOX PROTEIN; IMIDAZOLE DERIVATIVE; RK-33 COMPOUND;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER INHIBITION; CANCER STEM CELL; CARCINOGENIC ACTIVITY; CONTROLLED STUDY; CORRELATION ANALYSIS; DNA REPLICATION; DRUG CYTOTOXICITY; DRUG EFFECT; DRUG MECHANISM; DRUG TARGETING; ENZYME INHIBITION; EWING SARCOMA; EWING SARCOMA CELL LINE; FEMALE; GENE EXPRESSION; GENE SILENCING; HEMATOPOIETIC STEM CELL; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MESENCHYME CELL; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEOMICS; QUANTITATIVE ANALYSIS; RNA INTERFERENCE; RNA TRANSLATION; TISSUE MICROARRAY; TUMOR XENOGRAFT; ANIMAL; DEFICIENCY; DRUG EFFECTS; DRUG SCREENING; ENZYMOLOGY; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; MOLECULARLY TARGETED THERAPY; TUMOR CELL LINE;

ANIMALS; APOPTOSIS; AZEPINES; CELL LINE, TUMOR; DEAD-BOX RNA HELICASES; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE KNOCKDOWN TECHNIQUES; HUMANS; IMIDAZOLES; MICE; MOLECULAR TARGETED THERAPY; SARCOMA, EWING; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84941712220     PISSN: 09509232     EISSN: 14765594     Source Type: Journal    
DOI: 10.1038/onc.2015.336     Document Type: Article

References (39)

1. Italiano A, Mathoulin-Pelissier AS, Cesne AL, Terrier P, Bonvalot S, Collin F et al. Trends in survival for patients with metastatic soft-tissue sarcoma. Cancer 2011; 117: 1049-1054.
2. Abdelhaleem M. Do human RNA helicases have a role in cancer? Biochim Biophys Acta 2004; 1704: 37-46.
3. Fukumura J, Noguchi E, Sekiguchi T, Nishimoto T. A temperature-sensitive mutant of the mammalian RNA helicase, DEAD-BOX X isoform, DBX, defective in the transition from G1 to S phase. J Biochem 2003; 134: 71-82.
4. Lai MC, Chang WC, Shieh SY, Tarn WY. DDX3 regulates cell growth through translational control of cyclin E1. Mol Cell Biol 2010; 30: 5444-5453.
5. Lai MC, Lee YH, Tarn WY. The DEAD-box RNA helicase DDX3 associates with export messenger ribonucleoproteins as well as tip-associated protein and participates in translational control. Mol Biol Cell 2008; 19: 3847-3858.
6. Soto-Rifo R, Rubilar PS, Limousin T, Breyne S de, Décimo D, Ohlmann T. DEAD-box protein DDX3 associates with eIF4F to promote translation of selected mRNAs. EMBO J 2012; 31: 3745-3756.
7. Bol GM, Tran PT, Vesuna F, Xie M, van Diest PJ, Raman V. RK-33, a novel small molecule for lung cancer therapy via inhibition of NHEJ [5720]. Proceedings of the 103rd Annual Meeting of the American Association for Cancer Research. Cancer Res: Chicago, IL, USA, 2012, Abstract #5720.
8. Kondaskar A, Kondaskar S, Kumar R, Fishbein JC, Muvarak N, Lapidus RG et al. Novel, broad spectrum anti-cancer agents containing the tricyclic 5:7:5-fused diimidazodiazepine ring system. ACS Med Chem Lett 2010; 2: 252-256.
9. Bol GM, Vesuna AF, Xie M, Zeng J, Aziz K, Gandhi N et al. Targeting DDX3 with a small molecular inhibitor for lung cancer therapy. EMBO Mol Med 2015; 7: 648-669.
10. Kirsch DG, Dinulescu DM, Miller LB, Grimm J, Santiago PM, Young NP et al. A spatially and temporally restricted mouse model of soft tissue sarcoma. Nat Med 2007; 13: 992-997.
11. Garbelli A, Radi M, Falchi F, Beermann S, Zanoli S, Manetti F et al. Targeting the human DEAD-box polypeptide 3 (DDX3) RNA helicase as a novel strategy to inhibit viral replication. Curr Med Chem 2011; 18: 3015-3027.
12. Awad O, Yustein JT, Shah P, Gul N, Katuri V, O'Neill A et al. High ALDH activity identifies chemotherapy-resistant Ewing's sarcoma stem cells that retain sensitivity to EWS-FLI1 inhibition. PLoS One 2010; 5: e13943.
13. Italiano A, Sung YS, Zhang L, Singer S, Maki RG, Coindre JM et al. High prevalence of CIC fusion with double-homeobox (DUX4) transcription factors in EWSR1-negative undifferentiated small blue round cell sarcomas. Genes Chromosomes Cancer 2012; 51: 207-218.
14. Specht K, Sung YS, Zhang L, Richter GH, Fletcher CD, Antonescu CR. Distinct transcriptional signature and immunoprofile of CIC-DUX4 fusion-positive round cell tumors compared to EWSR1-rearranged Ewing sarcomas: further evidence toward distinct pathologic entities. Genes Chromosomes Cancer 2014; 53: 622-633.
15. Miao X, Yang ZL, Xiong L, Zou Q, Yuan Y, Li J et al. Nectin-2 and DDX3 are biomarkers for metastasis and poor prognosis of squamous cell/adenosquamous carcinomas and adenocarcinoma of the gallbladder. Int J Clin Exp Pharm 2013; 6: 179-190.
16. Bol GM, Raman V, Groep P, van der, Vermeulen JF, PAtel AH, Van der Wall E et al. Expression of the RNA helicase DDX3 and the hypoxia response in breast cancer. PLoS One 2013; 8: e63548.
17. Geissler R, Golbik RP, Behrens SE. The DEAD-box helicase DDX3 supports the assembly of functional 80 S ribosomes. Nucleic Acids Res 2012; 40: 4998-5011.
18. Lee CS, Dias AP, Jedrychowski M, Patel AH, Hsu JL, Reed R. Human DDX3 functions in translation and interacts with the translation initiation factor eIF3. Nucleic Acids Res 2008; 36: 4708-4718.
19. Shih JW, Tsai TY, Chao CH, Wu Lee YH. Candidate tumor suppressor DDX3 RNA helicase specifically represses cap-dependent translation by acting as an eIF4E inhibitory protein. Oncogene 2008; 27: 700-714.
20. Robinson G, Parker M, Kranenburg TA, Lu C, Chen X, Ding L et al. Novel mutations target distinct subgroups of medulloblastoma. Nature 2012; 488: 43-48.
21. Chang PC, Chi CW, Chau GY, Li FY, Tsai YH, Wu JC et al. DDX3, a DEAD box RNA helicase, is deregulated in hepatitis virus-associated hepatocellular carcinoma and is involved in cell growth control. Oncogene 2006; 25: 1991-2003.
22. Wu DW, Lee MC, Wang J, Chen CY, Cheng YQ, Lee H. DDX3 loss by p53 inactivation promotes tumor malignancy via the MDM2/Slug/E-cadherin pathway and poor patient outcomes in non-small-cell lung cancer. Oncogene 2014; 33: 1515-1516.
23. Sun M, Song L, Zhou T, Gillespie GY, Jope RS. The role of DDX3 in regulating Snail. Biochim Biophys Acta 2011; 1813: 438-447.
24. Sun M, Song L, Li Y, Zhou T, Jope RS. Identification of an antiapoptotic protein complex at death receptors. Cell Death Differ 2008; 15: 1887-1900.
25. Sun M, Zhou T, Jonasch E, Jope RS. DDX3 regulates DNA damage-induced apoptosis and p53 stabilization. Biochim Biophys Acta 2013; 1833: 1489-1497.
26. Botlagunta M, Vesuna F, Mironchik Y, Raman A, Lisok Jr A, Winnard P et al. Oncogenic role of DDX3 in breast cancer biogenesis. Oncogene 2008; 27: 3912-3922.
27. Nygren P, Larsson R. Differential in vitro sensitivity of human tumor and normal cells to chemotherapeutic agents and resistance modulators. Int J Cancer 1991; 48: 598-604.
28. Velikodvorskaya T, Fatima N, Fountain RQ, DeSoto JA. The comparative efficacy of the PARP inhibitors AG14361, ABT888 and AZD2281 in the treatment of triple negative and BRCA1 breast cancer. Cancer Res 2010; 70: 663.
29. Toretsky JA, Erkizan V, Levenson A, Abaan OD, Parvin JD, Cripe TP et al. Oncoprotein EWS-FLI1 activity is enhanced by RNA helicase A. Cancer Res 2006; 1: 5574-5581.
30. Erkizan HV, Kong Y, Merchant M, Schlottmann S, Barber-Rotenberg JS, Yuan L et al. A small molecule blocking oncogenic protein EWS-FLI1 interaction with RNA helicase A inhibits growth of Ewing's sarcoma. Nat Med 2009; 15: 750-756.
31. Sison EA, Rau RE, McIntyre E, Li L, Small S, Brown P. MLL-rearranged acute lymphoblastic leukaemia stem cell interactions with bone marrow stroma promote survival and therapeutic resistance that can be overcome with CXCR4 antagonism. Br J Haematol 2013; 160: 785-797.
32. Hazelton BJ, Houghton JA, Parham DM, Douglass EC, Torrance PM, Holt H et al. Characterization of cell lines derived from xenografts of childhood rhabdomyosarcoma. Cancer Res 1987; 47: 4501-4507.
33. Gonzalez-Nieto D, Li L, Kohler A, Ghiaur G, Ishikawa E, Sengupta A et al. Connexin-43 in the osteogenic BM niche regulates its cellular composition and the bidirectional traffic of hematopoietic stem cells and progenitors. Blood 2012; 119: 5144-5154.
34. Herbrich SM, Cole Jr RN, West KP, Schulze K, Yager DJ, Groopman JD et al. Statistical inference from multiple iTRAQ experiments without using common reference standards. J Proteome Res 2013; 12: 594-604.
35. Pierce A, Unwin RD, Evans CA, Griffiths S, Carney L, Zhang L et al. Eight-channel iTRAQ enables comparison of the activity of six leukemogenic tyrosine kinases. Mol Cell Proteomics 2008; 7: 853-863.
36. Ross PL, Huang YN, Marchese JN, Williamson B, Parker K, Hattan S et al. Multiplexed protein quantitation in Saccharomyces cerevisiae using amine-reactive isobaric tagging reagents. Mol Cell Proteomics 2004; 3: 1154-1169.
37. Wang Y, Yang F, Gritsenko MA, Wang Y, Clauss T, Liu T et al. Reversed-phase chromatography with multiple fraction concatenation strategy for proteome profiling of human MCF10A cells. Proteomics 2011; 11: 2019-2026.
38. Jensen LJ, Kuhn M, Stark M, Chaffron S, Creevey C, Muller J et al. STRING 8-a global view on proteins and their functional interactions in 630 organisms. Nucleic Acids Res 2009; 37: D412-D416.
39. Smyth GK. Linear models and empirical bayes methods for assessing differential expression in microarray experiments. Stat Appl Genet Mol Biol 2004; 3: 1.